Molecular mechanism underlying St. John's wort drug interactions

Current Drug Metabolism

Volumn 9, Issue 10, 2008, Pages 1027-1037

  Kober, Maike ^a   Pohl, Kerstin ^a   Efferth, Thomas ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Chemotherapy; CYP induction; Drug interaction; Pgp induction; Photodynamic therapy (PDT); Photophysical diagnosis (PPD); PXR activation; St. John's wort (SJW)

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIASTHMATIC AGENT; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYTOSTATIC AGENT; DACARBAZINE; DIGOXIN; DOCETAXEL; ETOPOSIDE; FEXOFENADINE; FLAVONOID; GLYCOPROTEIN P; HUMAN SERUM ALBUMIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPERFORIN; HYPERICIN; HYPERICUM PERFORATUM EXTRACT; HYPERIN; IMATINIB; IMMUNOSUPPRESSIVE AGENT; IRINOTECAN; OPIATE DERIVATIVE; ORAL CONTRACEPTIVE AGENT; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TETRACYCLIC ANTIDEPRESSANT AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; DRUG DERIVATIVE; PERYLENE;

AREA UNDER THE CURVE; BLOOD TOXICITY; BREAKTHROUGH BLEEDING; CELLULAR DISTRIBUTION; CLINICAL TRIAL; CYTOTOXICITY; DEPRESSION; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERICUM PERFORATUM; MAXIMUM PLASMA CONCENTRATION; MOLECULAR DYNAMICS; NONHUMAN; PHOTODERMATOSIS; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TEMPERATURE SENSITIVITY; UNWANTED PREGNANCY; ANIMAL; ENZYME INDUCTION; HERB DRUG INTERACTION; HYPERICUM; PHOTOCHEMOTHERAPY; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 CYP3A; ENZYME INDUCTION; HERB-DRUG INTERACTIONS; HUMANS; HYPERICUM; P-GLYCOPROTEIN; PERYLENE; PHOTOCHEMOTHERAPY;

EID: 62749096878     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920008786927767     Document Type: Review

References (169)

1. Blumenthal, M.; Goldberg, A.; Brinckmann, J. Herbal Medicine: Expanded Commission E Monographs, Integrative Medicine Communications: Newton (MA), USA, 2000.
2. Wichtl, M. Herbal Drugs and Phytopharmaceuticals, CRC Press: Boca Raton (FL), USA, 1994.
3. Fetrow, C.W.; Avila, J.R. Professional's Handbook of Complementary and Alternative Medicines, Springhouse Corporation: Springhouse (PA), USA, 1999.
4. Culpeper, N. The English Physician or an Astrologo-physical Discourse on the Vulgar Herbs of this Nation, Nathanial Brook: London, England, 1652.
5. Monograph. Hypericum perforatum. Altern. Med. Rev., 2004, 9(3), 318-325.
6. Schulz, V.; Hänsel, R. Rationale Phytotherapie, Springer: Berlin, Germany, 1999
7. Butterweck, V.; Schmidt, M. St. John's wort: role of active compounds for its mechanism of action and efficacy. Wien. Med. Wochenschr., 2007, 157(13-14), 356-361.
8. Beerhues, L. Hyperforin. Phytochemistry, 2006, 67(20), 2201-2207.
9. Melzer, M.; Fuhrken, D.; Kolkmann, R. Hyperforin im Johanniskraut. Hauptwirkstoff oder nur Leitsubstanz? Dtsch. Apoth. Ztg., 1998, 13, 4754-4760.
10. Cellarova, E.; Daxnerova, Z.; Kimakova, K.; Haluskova, J. The variability of the hypericin content in the regenerants of Hypericum perforatum. Acta Biotechnol., 1994, 14, 267-274.
11. Bergonzi, M.C.; Bilia, A.R.; Gallori, S.; Guerrini, D.; Vincieri, F.F. Variability in the content of the constituents of Hypericum perforatum L.; some commercial extracts. Drug Dev. Ind. Pharm., 2001, 27(6), 491-497.
12. Lawvere, S.; Mahoney, M.C. St. John's wort. Am. Fam. Physician, 2005, 72(11), 2249-2254.
13. Kubin, A.; Wierrani, F.; Burner, U.; Alth, G.; Grunberger, W. hypericin-the facts about a controversial agent. Curr. Pharm. Des., 2005, 11(2), 233-253.
14. Orth, H.C.J.; Rentel, C.; Schmidt, P.C. Isolation, purity analysis and stability of hyperforin as a standard material from Hypericum perforatum L. J. Pharm. Pharmacol., 1999, 51(2), 193-200.
15. Hertog, M.G.; Feskens, E.J.; Kromhout, D. Antioxidant flavonols and coronary heart disease risk. Lancet, 1997, 349(9053), 699.
16. Sparenberg, B.; Demisch, L.; Hölzl, J. Untersuchungen über anti-depressive Wirkstoffe von Johanniskraut. Pharm. Z. Wiss., 1993, 138, 50-54.
17. Linde, K.; Mulrow, C.D.; Berner, M.; Egger, M. St John's wort for depression. Cochrane Database Syst. Rev., 2005, 2, CD000448.
18. Klepser, T.B.; Doucette, W.R.; Horton, M.R.; Buys, L.M.; Ernst, M.E.; Ford, J.K. Assessment of patients' perceptions and beliefs regarding herbal therapies. Pharmacotherapy, 2000, 20(1), 83-87.
19. Martin-Facklam, M.; Rieger, K.; Riedel, K.D.; Burhenne, J.; Walter-Sack, I.; Haefeli, W.E. Undeclared exposure to St. John's Wort in hospitalized patients. Br. J. Clin. Pharmacol., 2004, 58(4), 437-441.
20. Zhou, S.; Gao, Y.; Jiang, W.; Huang, M.; Xu, A.; Paxton, J.W. Interactions of herbs with cytochrome P450. Drug Metab. Dispos., 2003, 35(1), 35-98.
21. Thomas, C.; Pardini, R.S. Oxygen dependence of hypericin-induced phototoxicity to EMT6 mouse mammary carcinoma cells. Photochem. Photobiol., 1992, 55(6), 831-837.
22. Kiesslich, T.; Krammer, B.; Plaetzer, K. Cellular mechanisms and prospective applications of hypericin in photodynamic therapy. Curr. Med. Chem., 2006, 13(18), 2189-2204.
23. Sattler, S.; Schaefer, U.; Schneider, W.; Hoelzl, J.; Lehr, C.M. Binding, uptake, and transport of hypericin by Caco-2 cell monolayers. J. Pharm. Sci., 1997, 86(10), 1120-1126.
24. Uzdensky, A.B.; Ma, L.W.; Iani, V.; Hjortland, G.O.; Steen, H.B.; Moan, J. Intracellular localisation of hypericin in human glioblastoma and carcinoma cell lines. Lasers Med. Sci., 2001, 16(4), 276-283.
25. English, D.S.; Doyle, R.T.; Petrich, J.W.; Haydon, P.G. Photochem. Photobiol., 1999, 69(3), 301-305.
26. Miskovsky, P.; Sureau, F.; Chinsky, L.; Turpin, P.Y. Photochem. Photobiol., 1995, 62(3), 546-549.
27. Miskovsky, P. hypericin - a new antiviral and antitumor photosensitizer: mechanism of action and interaction with biological macromolecules. Curr. Drug Targets, 2002, 3(1), 55-84.
28. Medical Products Agency St John's Wort may influence other medications. Sweden, 2002.
29. Ernst, E. Second thoughts about safety of St John's wort. Lancet, 1999, 354(9195), 2014-2016.
30. Madabushi, R.; Frank, B.; Drewelow, B.; Derendorf, H.; Butterweck, V. hyperforin in St. John's wort drug interactions. Eur. J. Clin. Pharmacol., 2006, 62(3), 225-233.
31. McCune, J.S.; Hatfield, A.J.; Blackburn, A.A.; Leith, P.O.; Livingston, R.B.; Ellis, G.K. Potential of chemotherapy-herb interactions in adult cancer patients. Support Care Cancer, 2004, 12(6), 454-462.
32. Meijerman, I.B., J.H.; Schellens, J.H. Herb-drug interactions in oncology: focus on mechanisms of induction. Oncologist, 2006, 11(7), 742-752.
33. Mathijssen, R.H.; Verweij, J.; de Bruijn, P.; Loos, W.J.; Sparreboom, A. Effects of St. John's wort on irinotecan metabolism. J. Natl. Cancer Inst., 2002, 94(16), 1247-1249.
34. Josefson, D. St John's wort interferes with chemotherapy, study shows. BMJ, 2002, 325(7362), 460.
35. Schmitt, J. Gefährdet Johanniskraut den Erfolg von Chemotherapie? Pharm. Unserer Zeit, 2003, 32(1), 8.
36. Hu, Z.; Yang, X.; Ho, P.C.; Chan, E.; Chan, S.Y.; Xu, C.; Li, X.; Zhu, Y.Z.; Duan, W.; Chen, X.; Huang, M.; Yang, H.; Zhou, S. St. John's Wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats. Pharm. Res., 2005, 22(6), 902-914.
37. Frye, R.F.; Fitzgerald, S.M.; Lagattuta, T.F.; Hruska, M.W.; Egorin, M.J. Effect of St John's wort on imatinib mesylate pharmacokinetics. Clin. Pharmacol. Ther., 2004, 76(4), 323-329.
38. Buchdunger, E.; Zimmermann, J.; Mett, H.; Meyer, T.; Muller, M.; Druker, B.J.; Lydon, N.B. Inhibition of the Ab1 protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res., 1996, 56(1), 100-104.
39. Druker, B.J.; Sawyers, C.L.; Kantarjian, H.; Resta, D.J.; Reese, S.F.; Ford, J.M.; Capdeville, R.; Talpaz, M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med., 2001, 344(14), 1038-1042.
40. Druker, B.J.; Talpaz, M.; Resta, D.J.; Peng, B.; Buchdunger, E.; Ford, J.M.; Lydon, N.B.; Kantarjian, H.; Capdeville, R.; Ohno-Jones, S.; Sawyers, C.L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med., 2001, 344(14), 1031-1037.
41. Smith, P.; Bullock, J.M.; Booker, B.M.; Haas, C.E.; Berenson, C.S.; Jusko, W.J. The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy, 2004, 24(11), 1508-1514.
42. Demetri, G.D.; von Mehren, M.; Blanke, C.D.; Van den Abbeele, A.D.; Eisenberg, B.; Roberts, P.J.; Heinrich, M.C.; Tuveson, D.A.; Singer, S.; Janicek, M.; Fletcher, J.A.; Silverman, S.G.; Silberman, S.L.; Capdeville, R.; Kiese, B.; Peng, B.; Dimitrijevic, S.; Druker, B.J.; Corless, C.; Fletcher, C.D.; Joensuu, H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med., 2002, 347(7), 472-480.
43. Novartis Pharmaceuticals Gleevec (imatinib mesylate) [full prescribing information]. East Hanover (NJ), USA, 2002.
44. Dagher, R.; Cohen, M.; Williams, G.; Rothmann, M.; Gobburu, J.; Robbie, G.; Rahman, A.; Chen, G.; Staten, A.; Griebel, D.; Pazdur, R. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin. Cancer Res., 2002, 8(10), 3034-3038.
45. Hamada, A.; Miyano, H.; Watanabe, H.; Saito, H. Interaction of imatinib mesilate with human P-glycoprotein. J. Pharmacol. Exp. Ther., 2003, 307(2), 824-828.
46. Smith, P.F.; Bullock, J.M.; Booker, B.M.; Haas, C.E.; Berenson, C.S.; Jusko, W.J. Induction of imatinib metabolism by hypericum perforatum. Blood, 2004, 104(4), 1229-1230.
47. Deininger, M.W.; O'Brien, S.G.; Ford, J.M.; Druker, B.J. Practical management of patients with chronic myeloid leukemia receiving imatinib. J. Clin. Oncol., 2003, 21(8), 1637-1647.
48. Peng, B.; Hayes, M.; Resta, D.; Racine-Poon, A.; Druker, B.J.; Talpaz, M.; Sawyers, C.L.; Rosamilia, M.; Ford, J.; Lloyd, P.; Capdeville, R. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J. Clin. Oncol., 2004, 22(5), 935-942.
49. Talpaz, M.; Silver, R.T.; Druker, B.J.; Goldman, J.M.; Gambacorti-Passerini, C.; Guilhot, F.; Schiffer, C.A.; Fischer, T.; Deininger, M.W.; Lennard, A.L.; Hochhaus, A.; Ottmann, O.G.; Gratwohl, A.; Baccarani, M.; Stone, R.; Tura, S.; Mahon, F.X.; Fernandes-Reese, S.; Gathmann, I.; Capdeville, R.; Kantarjian, H.M.; Sawyers, C.L. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood, 2002, 99(6), 1928-1937.
50. Komoroski, B.J.; Parise, R.A.; Egorin, M.J.; Strom, S.C.; Venkataramanan, R. Effect of the St. John's wort constituent hyperforin on docetaxel metabolism by human hepatocyte cultures. Clin. Cancer Res., 2005, 11(19 Pt 1), 6972-6979.
51. Cortes, J.E.; Pazdur, R. Docetaxel. J. Clin. Oncol., 1995, 13(10), 2643-2655.
52. Hong, W K. The current status of docetaxel in solid tumors. An M. D. Anderson Cancer Center Review. Oncology (Williston Park N.Y.), 2002, 16(6 Suppl 6), 9-15.
53. Trudeau, M.E. Docetaxel: a review of its pharmacology and clinical activity. Can. J. Oncol., 1996, 6(1), 443-457.
54. Garcia, P.; Braguer, D.; Carles, G.; el Khyari, S.; Barra, Y.; de Ines, C.; Barasoain, I.; Briand, C. Comparative effects of taxol and Taxotere on two different human carcinoma cell lines. Cancer Chemother. Pharmacol., 1994, 34(4), 335-343.
55. Lavelle, F.; Bissery, M.C.; Combeau, C.; Rion, J.F.; Vrignaud, P.; Andre, S. Preclinical evaluation of docetaxel (Taxotere). Semin. Oncol, 1995, 22(2 Suppl 4), 3-16.
56. Biber, A.; Fischer, H.; Romer, A.; Chatterjee, S.S. Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteers. Pharmacopsychiatry, 1998, 31(Suppl 1), 3643.
57. Bienvenu, T.; Rey, E.; Pons, G.; d'Athis, P.; Olive, G. A simple non-invasive procedure for the investigation of cytochrome P450 IIIA dependent enzymes in humans. Int. J. Clin. Pharmacol. Ther. Toxicol., 1991, 29(11), 441-445.
58. Michalets, E.L. Update: clinically significant cytochromc P450 drug interactions. Pharmacotherapy, 1998, 18(1), 84-112.
59. Smith, D.A.; Abel, S.M.; Hyland, R.; Jones, B.C. Human cytochrome P450s: selectivity and measurement in vivo, Xenobiotica, 1998, 28(12), 1095-1128.
60. Bauer, S.; Stormer, E.; Kerb, R.; Johne, A.; Brockmoller, J.; Roots, I. Differential effects of Saint John's Wort (hypericum perforatum) on the urinary excretion of D-glucaric acid and 6beta-hydroxycortisol in healthy volunteers. Eur. J. Clin. Pharmacol., 2002, 58(9), 581-585.
61. Roby, C.A.; Anderson, G.D.; Kantor, E.; Dryer, D.A.; Burstein, A.H. St John's Wort: effect on CYP3A4 activity. Clin. Pharmacol. Ther., 2000, 67(5), 451-457.
62. Wenk, M.; Todesco, L.; Krahenbuhl, S. Effect of St John's wort on the activities of CYP1 A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females. Br. J. Clin. Pharmacol., 2004, 57(4), 495-499.
63. Dresser, G.K.; Schwarz, U.I.; Wilkinson, G.R.; Kim, R.B. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin. Pharmacol. Ther., 2003, 73(1), 41-50.
64. Gurley, B.J.; Gardner, S.F.; Hubbard, M.A.; Williams, D.K.; Gentry, W.B.; Cui, Y.; Ang, C.Y. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions. in humans. Clin. Pharmacol. Ther., 2002, 72(3), 276-287.
65. Hall, S.D.; Wang, Z.; Huang, S.M.; Hamman, M.A.; Vasavada, N.; Adigun, A.Q.; Hilligoss, J.K.; Miller, M.; Gorski, J.C. The interaction between St John's wort and an oral contraceptive. Clin. Pharmacol. Ther., 2003, 74(6), 525-535.
66. Wang, Z.; Gorski, J.C.; Hamman, M.A.; Huang, S.M.; Lesko, L.J.; Hall, S.D. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin. Pharmacol Ther., 2001, 70(4), 317-326.
67. Xie, R.; Tan, L.H.; Polasek, E.C.; Hong, C.; Teillol-Foo, M.; Gordi, T.; Sharma, A.; Nickens, D.J.; Arakawa, T.; Knuth, D.W.; Antal, E.J. CYP3A and P-glycoprotein activity induction with St. John's Wort in healthy volunteers from 6 ethnic populations. J Clin. Pharmacol., 2005, 45(3), 352-356.
68. Markowitz, J.S.; Donovan, J.L.; DeVane, C.L.; Taylor, R.M.; Ruan, Y.; Wang, J.S.; Chavin, K.D. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA, 2003, 290(11), 1500-1504.
69. Ereshefsky, B.; Gewertz, N.; Lam, Y.W.F. Determination of St John's wort differential metabolism at CYP2D6 and CYP3A4, using dextromethorphan probe methodology. 39th Annual NCDEU Meeting. Boca Raton (FL), USA 1999.
70. Arold, G.; Donath, F.; Maurer, A. (2001) The influence of St John's wort extract (St John's wort, Esbericum capsules) on the pharmacokinetics of alprazolam, caffeine, tolbutamide and digoxin in man. in 5th EACPT Congress. Odense: Pharmacol Toxicol 2001.
71. Durr, D,; Stieger, B.; Kullak-Ublick, G.A.; Rentsch, K.M.; Steinert, H.C.; Meier, P.J.; Fattinger, K. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin. Pharmacol. Ther., 2000, 68(6), 598-604.
72. Zhou, S.; Lim, L.Y.; Chowbay, B. Herbal modulation of P-glycoprotein. Drug Metab. Dispos., 2004, 36(1), 57-104.
73. Blumberg, B.; Sabbagh, W., Jr.; Juguilon, H.; Bolado, J., Jr.; van Meter, C.M.; Ong, E.S.; Evans, R.M. SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev., 1998, 12(20), 3195-3205.
74. Bertilsson, G.; Heidrich, J.; Svensson, K.; Asman, M.; Jendeberg, L.; Sydow-Backman, M.; Ohlsson, R.; Postlind, H.; Blomquist, P.; Berkenstam, A. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc. Natl. Acad. Sci. U.S.A., 1998, 95(21), 12208-12213.
75. Falkner, K.C.; Pinaire, J.A.; Xiao, G.H.; Geoghegan, T.E.; Prough, R.A. Regulation of the rat glutathione S-transferase A2 gene by glucocorticoids: involvement of both the glucocorticoid and pregnane X receptors. Mol. Pharmacol., 2001, 60(3), 611-619.
76. Xie, W.; Yeuh, M.F.; Radominska-Pandya, A.; Saini, S.P.; Negishi, Y.; Bottroff, B.S.; Cabrera, G.Y.; Tukey, R.H.; Evans, R.M. Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor. Proc. Natl. Acad. Sci. U.S.A., 2003, 100(7), 4150-4155.
77. Sonoda, J.; Xie, W.; Rosenfeld, J.M.; Barwick, J.L.; Guzelian, P.S.; Evans, R.M. Regulation of a xenobiotic sulfonation cascade by nuclear pregnane X receptor (PXR). Proc. Natl. Acad. Sci. U.S.A., 2002, 99(21), 13801-13806.
78. Goodwin, B.; Moore, L.B.; Stoltz, C.M.; McKee, D.D.; Kliewer, S.A. Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol. Pharmacol., 2001, 60(3), 427-431.
79. Chen, Y.; Ferguson, S.S.; Negishi, M.; Goldstein, J.A. Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J. Pharmacol. Exp. Ther., 2004, 308(2), 495-501.
80. Bodo, A.; Bakos, E.; Szeri, F.; Varadi, A.; Sarkadi, B. The role of multidrug transporters in drug availability, metabolism and toxicity. Toxicol. Lett., 2003, 140-141, 133-143.
81. Gatmaitan, Z.C.; Arias, I.M. Structure and function of P-glycoprotein in normal liver and small intestine. Adv. Pharmacol., 1993, 24, 77-97.
82. Lown, K.S.; Mayo, R.R.; Leichtman, A.B.; Hsiao, H.L.; Turgeon, D.K.; Schmiedlin-Ren, P.; Brown, M.B.; Guo, W.; Rossi, S.J.; Benet, L.Z.; Watkins, P.B. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther., 1997, 62(3), 248-260.
83. Brattström, A. Der Johanniskrautextrakt ZE 117. Dtsch. Apoth. Ztg., 2002, 142(30), 97-100.
84. Johne, A.; Brockmoller, J.; Bauer, S.; Maurer, A.; Langheinrich, M.; Roots, I. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin. Pharmacol. Ther., 1999, 66(4), 338-345.
85. Mueller, S.C.; Uehleke, B.; Woehling, H.; Petzsch, M.; Majcher-Peszynska, J.; Hehl, E.M.; Sievers, H.; Frank, B.; Riethling, A.K.; Drewelow, B. Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin. Clin. Pharmacol. Ther., 2004, 75(6), 546-557.
86. Wang, Z.; Hamman, M.A.; Huang, S.M.; Lesko, L.J.; Hall, S.D. Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin. Pharmacol. Ther., 2002, 71(6), 414-420.
87. Bosch, T.M.; Meijerman, I.; Beijnen, J.H.; Schellens, J.H. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin. Pharmacokinet., 2006, 45(3), 253-285.
88. Schinkel, A.H.; Jonker, J.W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev., 2003, 55(1), 3-29.
89. Sparreboom, A.; Danesi, R.; Ando, Y.; Chan, J.; Figg, W.D. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist. Updat., 2003, 6(2), 71-84.
90. Komoroski, B.J.; Zhang, S.; Cai, H.; Hutzler, J.M.; Frye, R.; Tracy, T.S.; Strom, S.C.; Lehmann, T.; Ang, C.Y.; Cui, Y.Y.; Venkataramanan, R. Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures. Drug Metab. Dispos., 2004, 32(5), 512-518.
91. Markowitz, J.S.; DeVane, C.L.; Boulton, D.W.; Carson, S.W.; Nahas, Z.; Risch, S.C. Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci., 2000, 66(9), PL133-139.
92. Roby, C.A.; Dryer, D.A.; Burstein, A.H. St. John's wort: effect on CYP2D6 activity using dextromethorphan-dextrorphan ratios. J. Clin. Psychopharmacol., 2001, 21(5), 530-532.
93. Gewertz, N.; Ereshefsky, B.; Lam, Y.W.F. Determination of the differential effects of St John's wort on the CYP1A2 and NAT2 metabolic pathways using caffeine probe methodology. in 39th Annual NCDEU Meeting. Boca Raton (FL), USA, 1999.
94. Wang, L.S.; Zhou, G.; Zhu, B.; Wu, J.; Wang, J.G.; Abd El-Aty, A.M.; Li, T.; Liu, J.; Yang, T.L.; Wang, D.; Zhong, X.Y.; Zhou, H.H. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin. Pharmacol. Ther., 2004, 75(3), 191-197.
95. Chang, M.; Tybring, G.; Dahl, M.L.; Gotharson, E.; Sagar, M.; Seensalu, R.; Bertilsson, L. Interphenotype differences in disposition and effect on gastrin levels of omeprazole - suitability of omeprazole as a probe for CYP2C19. Br. J. Clin. Pharmacol., 1995, 39(5), 511-518.
96. Jiang, X.; Williams, K.M.; Liauw, W.S.; Ammit, A.J.; Roufogalis, B.D.; Duke, C.C.; Day, R.O.; McLachlan, A.J. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br. J. Clin. Pharmacol., 2004, 57(5), 592-599.
97. Johne, A.; Schmider, J.; Brockmoller, J.; Stadelmann, A.M.; Stormer, E.; Bauer, S.; Scholler, G.; Langheinrich, M.; Roots, I. Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort (Hypericum perforatum). J. Clin. Psychopharmacol., 2002, 22(1), 46-54.
98. Kaminsky, L.S.; de Morais, S.M.; Faletto, M.B.; Dunbar, D.A.; Goldstein, J.A. Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. Mol. Pharmacol., 1993, 43(2), 234-239.
99. Venkatakrishnan, K.; Greenblatt, D.J.; von Moltke, L.L.; Schmider, J.; Harmatz, J.S.; Shader, R.I. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4. J. Clin. Pharmacol., 1998, 38(2), 112-121.
100. Choudhuri, S.; Valerio, L.G., Jr. Usefulness of studies on the molecular mechanism of action of herbals/botanicals: The case of St. John's wort. J. Biochem. Mol. Toxicol., 2005, 19(1), 1-11.
101. Kliewer, S.A.; Goodwin, B.; Willson, T.M. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr. Rev., 2002, 23(5), 687-702.
102. Sekine, A.; Saito, S.; Iida, A.; Mitsunobu, Y.; Higuchi, S.; Harigae, S.; Nakamura, Y. Identification of single-nucleotide polymorphisms (SNPs) of human N-acetyltransferase genes NAT1, NAT2, AANAT, ARD1 and L1CAM in the Japanese population. J. Hum. Genet., 2001, 46(6), 314-319.
103. Robert, J.; Morvan, V.L.; Smith, D.; Pourquier, P.; Bonnet, J. Predicting drug response and toxicity based on gene polymorphisms. Crit. Rev. Oncol. Hematol., 2005, 54(3), 171-196.
104. Beijnen, J.H.; Schellens, J.H. Drug interactions in oncology. Lancet Oncol., 2004, 5(8), 489-496.
105. Shibayama, Y.; Kawachi, A.; Onimaru, S.; Tokunaga, J.; Ikeda, R.; Nishida, K.; Kuchiiwa, S.; Nakagawa, S.; Takamura, N.; Motoya, T.; Takeda, Y.; Yamada, K. Effect of pre-treatment with St John's Wort on nephrotoxicity of cisplatin in rats. Life Sci., 2007, 81(2), 103-108.
106. Hu, Z.P.; Yang, X.X.; Chan, S.Y.; Xu, A.L.; Duan, W.; Zhu, Y.Z.; Sheu, F.S.; Boelsterli, U.A.; Chan, E.; Zhang, Q.; Wang, J.C.; Ee, P.L.; Koh, H.L.; Huang, M.; Zhou, S.F. St. John's wort attenuates irinotecan-induced diarrhea via down-regulation of intestinal proinflammatory cytokines and inhibition of intestinal epithelial apoptosis. Toxicol. Appl. Pharmacol., 2006, 216(2), 225-237.
107. Birdsall, T.C. St. John's wort and irinotecan-induced diarrhea. Toxicol. Appl. Pharmacol., 2007, 220(1), 108; author reply 109-10.
108. Gobbi, M.; Moia, M.; Pirona, L.; Morizzoni, P.; Mennini, T. In vitro binding studies with two hypericum perforatum extracts - hyperforin, hypericin and biapigenin - on 5-HT6, 5-HT7, GABA(A)/ benzodiazepine, sigma, NPY-Y1/Y2 receptors and dopamine transporters. Pharmacopsychiatry, 2001, 34(Suppl 1), S45-48.
109. Raffa, R.B. Screen of receptor and uptake-site activity of hypericin component of St. John's wort reveals sigma receptor binding. Life Sci., 1998, 62(16), PL265-270.
110. Simmen, U.; Higelin, J.; Berger-Buter, K.; Schaffner, W.; Lundstrom, K. Neurochemical studies with St. John's wort in vitro. Pharmacopsychiatry, 2001, 34(Suppl 1), S137-142.
111. de Witte, P.; Agostinis, P.; Van Lint, J.; Merlevede, W.; Vandenheede, J.R. Inhibition of epidermal growth factor receptor tyrosine kinase activity by hypericin. Biochem. Pharmacol., 1993, 46(11), 1929-1936.
112. Agostinis, P.; Donella-Deana, A.; Cuveele, J.; Vandenbogaerde, A.; Sarno, S.; Merlevede, W.; de Witte, P. A comparative analysis of the photosensitized inhibition of growth-factor regulated protein kinases by hypericin-derivatives. Biochem. Biophys. Res. Commun., 1996, 220(3), 613-617.
113. Agostinis, P.; Vandenbogaerde, A.; Donella-Deana, A.; Pinna, L.A.; Lee, K.T.; Goris, J.; Merlevede, W.; Vandenheede, J.R.; De Witte, P. Photosensitized inhibition of growth factor-regulated protein kinases by hypericin. Biochem. Pharmacol., 1995, 49(11), 1615-1622.
114. Frew, T.; Powis, G.; Berggren, M.; Abraham, R.T.; Ashendel, C.L.; Zalkow, L.H.; Hudson, C.; Qazia, S.; Gruszecka-Kowalik, E.; Merriman, R.; et al. A multiwell assay for inhibitors of phosphatidylinositol-3-kinase and the identification of natural product inhibitors. Anticancer Res., 1994, 14(6B), 2425-2428.
115. Baureithel, K.H.; Buter, K.B.; Engesser, A.; Burkard, W.; Schaffner, W. Inhibition of benzodiazepine binding in vitro by amentoflavone, a constituent of various species of Hypericum. Pharm. Acta. Helv., 1997, 72(3), 153-157.
116. Chatterjee, S.S.; Bhattacharya, S.K.; Wonnemann, M.; Singer, A.; Muller, W.E. Hyperforin as a possible antidepressant component of hypericum extracts. Life Sci., 1998, 63(6), 499-510.
117. Chatterjee, S.S.; Noldner, M.; Koch, E.; Erdelmeier, C. Antidepressant activity of hypericum perforatum and hyperforin: the neglected possibility. Pharmacopsychiatry, 1998, 31(Suppl 1), 7-15.
118. Roz, N.; Mazur, Y.; Hirshfeld, A.; Rehavi, M. Inhibition of vesicular uptake of monoamines by hyperforin. Life Sci., 2002, 71(19), 2227-2237.
119. Buchholzer, M.L.; Dvorak, C.; Chatterjee, S.S.; Klein, J. Dual modulation of striatal acetylcholine release by hyperforin, a constituent of St. John's wort. J. Pharmacol. Exp. Ther., 2002, 301(2), 714-719.
120. Jensen, A.G.; Hansen, S.H.; Nielsen, E.O. Adhyperforin as a contributor to the effect of Hypericum perforatum L. in biochemical models of antidepressant activity. Life Sci., 2001, 68(14), 1593-1605.
121. Muller, W.E.; Singer, A.; Wonnemann, M.; Hafner, U.; Rolli, M.; Schafer, C. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacopsychiatry, 1998, 31(Suppl 1), 16-21.
122. Gobbi, M.; Valle, F.D.; Ciapparelli, C.; Diomede, L.; Morazzoni, P.; Verotta, L.; Caccia, S.; Cervo, L.; Mennini, T. Hypericum perforatum L. extract does not inhibit 5-HT transporter in rat brain cortex. Naunyn Schmiedebergs Arch. Pharmacol., 1999, 360(3), 262-269.
123. Singer, A.; Wonnemann, M.; Muller, W.E. Hyperforin, a major antidepressant constituent of St. John's Wort, inhibits serotonin uptake by elevating free intracellular Na+1. J. Pharmacol. Exp. Ther., 1999, 290(3), 1363-1368.
124. Wonnemann, M.; Singer, A.; Siebert, B.; Muller, W.E. Evaluation of synaptosomal uptake inhibition of most relevant constituents of St. John's wort. Pharmacopsychiatry, 2001, 34(Suppl 1), S148-151.
125. Malandro, M.S.; Kilberg, M.S. Molecular biology of mammalian amino acid transporters. Annu. Rev. Biochem., 1996, 65, 305-336.
126. Muller, W.E.; Singer, A.; Wonnemann, M. Hyperforin - antidepressant activity by a novel mechanism of action. Pharmacopsychiatry, 2001, 34(Suppl 1), S98-102.
127. Wonnemann, M.; Singer, A.; Muller, W.E. Inhibition of synaptosomal uptake of 3H-L-glutamate and 3H-GABA by hyperforin, a major constituent of St. John's Wort: the role of amiloride sensitive sodium conductive pathways. Neuropsychopharmacology, 2000, 23(2), 188-197.
128. Putnik, K.; Stadler, P.; Schafer, C.; Koelbl, O. Enhanced radiation sensitivity and radiation recall dermatitis (RRD) after hypericin therapy - case report and review of literature. Radiat. Oncol., 2006, 1, 32.
129. D'Hallewin, M.A.; Kamuhabwa, A.R.; Roskams, T.; De Witte, P.A.; Baert, L. Hypericin-based fluorescence diagnosis of bladder carcinoma. BJU Int., 2002, 89(7), 760-763.
130. Dougherty, T.J. Photosensitizers: therapy and detection of malignant tumors. Photochem. Photobiol., 1987, 45(6), 879-889.
131. Dougherty, T.J.; Gomer, C.J.; Henderson, B.W.; Jori, G.; Kessel, D.; Korbelik, M.; Moan, J.; Peng, Q. Photodynamic therapy. J. Natl. Cancer Inst., 1998, 90(12), 889-905.
132. Firestone, R.A. Low-density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells. Bioconjug. Chem., 1994, 5(2), 105-113.
133. Siboni, G.; Weitman, H.; Freeman, D.; Mazur, Y.; Malik, Z.; Ehrenberg, B. The correlation between hydrophilicity of hypericins and helianthrone: internalization mechanisms, subcellular distribution and photodynamic action in colon carcinoma cells. Photochem. Photobiol. Sci., 2002, 1(7), 483-491.
134. Lee, M.; Roldan, M.C.; Haskell, M.K.; McAdam, S.R.; Hartley, J.A. In vitro photoinduced cytotoxicity and DNA binding properties of psoralen and coumarin conjugates of netropsin analogues: DNA sequence-directed alkylation and cross-link formation. J. Med. Chem., 1994, 37(8), 1208-1213.
135. D'Hallewin, M.A.; De Witte, P.A.; Waelkens, E.; Merlevede, W.; Baert, L. Fluorescence detection of flat bladder carcinoma in situ after intravesical instillation of hypericin. J. Urol., 2000, 164(2), 349-351.
136. Kamuhabwa, A.A.; Cosserat-Gerardin, I.; Didelon, J.; Notter, D.; Guillemin, F.; Roskams, T.; D'Hallewin, M.A.; Baert, L.; de Witte, P.A. Biodistribution of hypericin in orthotopic transitional cell carcinoma bladder tumors: implication for whole bladder wall photodynamic therapy. Int. J. Cancer, 2002, 97(2), 253-260.
137. Olivo, M.; Lau, W.; Manivasager, V.; Bhuvaneswari, R.; Wei, Z.; Soo, K.C.; Cheng, C.; Tan, P.H. Novel photodynamic diagnosis of bladder cancer: ex vivo fluorescence cytology using hypericin. Int. J. Oncol., 2003, 23(6), 1501-1504.
138. Brown, S.B.; Brown, E.A.; Walker, I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol., 2004, 5(8), 497-508.
139. Dolmans, D.E.; Fukumura, D.; Jain, R.K. Photodynamic therapy for cancer. Nat. Rev. Cancer, 2003, 3(5), 380-387.
140. Sibata, C.H.; Colussi, V.C.; Oleinick, N.L.; Kinsella, T.J. Photodynamic therapy in oncology. Expert Opin. Pharmacother., 2001, 2(6), 917-927.
141. Andreoni, A.; Colasanti, A.; Colasanti, P.; Mastrocinque, M.; Riccio, P.; Roberti, G. Laser photosensitization of cells by hypericin. Photochem. Photobiol., 1994, 59(5), 529-533.
142. VanderWerf, Q.M.; Saxton, R.E.; Chang, A.; Horton, D.; Paiva, M.B.; Anderson, J.; Foote, C.; Soudant, J.; Mathey, A.; Castro, D.J. Hypericin: a new laser phototargeting agent for human cancer cells. Laryngoscope, 1996, 106(4), 479-483.
143. Koren, H.; Schenk, G.M.; Jindra, R.H.; Alth, G.; Ebermann, R.; Kubin, A.; Koderhold, G.; Kreitner, M. Hypericin in phototherapy. J. Photochem. Photobiol. B., 1996, 36(2), 113-119.
144. Moan, J.; Berg, K. The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem. Photobiol., 1991, 53(4), 549-553.
145. Mizeret, J.C.; van den Bergh, H.E. Cylindrical fiberoptic light diffuser for medical applications. Lasers Surg. Med., 1996, 19(2), 159-167.
146. Bachowski, G.J.; Korytowski, W.; Girotti, A.W. Characterization of lipid hydroperoxides generated by photodynamic treatment of leukemia cells. Lipids, 1994, 29(7), 449-459.
147. Girotti, A.W. Mechanisms of lipid peroxidation. J. Free Radic. Biol. Med., 1985, 1(2), 87-95.
148. Grune, T.; Klotz, L.O.; Gieche, J.; Rudeck, M.; Sies, H. Protein oxidation and proteolysis by the nonradical oxidants singlet oxygen or peroxynitrite. Free Radic. Biol. Med., 2001, 30(11), 1243-1253.
149. Ito, T. Cellular and subcellular mechanisms of photodynamic action: the 1O2 hypothesis as a driving force in recent research. Photochem. Photobiol., 1978, 28(4-5), 493-508.
150. Midden, W.R.; Dahl, T.A. Biological inactivation by singlet oxygen: distinguishing O2(1 delta g) and O2(1 sigma g+). Biochim. Biophys. Acta, 1992, 1117(2), 216-222.
151. Ravanat, J.L.; Cadet, J. Reaction of singlet oxygen with 2′-deoxyguanosine and DNA. Isolation and characterization of the main oxidation products. Chem. Res. Toxicol., 1995, 8(3), 379-388.
152. Rosenthal, I.; Ben-Hur, E. Role of oxygen in the phototoxicity of phthalocyanines. Int. J. Radiat. Biol., 1995, 67(1), 85-91.
153. Valenzeno, D.P. Photomodification of biological membranes with emphasis on singlet oxygen mechanisms. Photochem. Photobiol., 1987, 46(1), 147-160.
154. Fehr, M.J.; Carpenter, S.L.; Petrich, J.W. The role of oxygen in the photoinduced antiviral activity of hypericin. Bioorg. Med. Chem. Lett., 1994, 4, 1339-1344.
155. Fehr, M.J.; McCloskey, M.C.; Petrich, J.W. Light-Induced Acidification by the Antiviral Agent Hypericin. J. Am. Chem. Soc., 1995, 117(6), 1833-1836.
156. Petrich, J.W. Excited-state intramolecular H-atom transfer in nearly symmetrical perylene quinones: hypericin, hypocrellin, and their analogues. Int. Rev. Phys. Chem., 2000, 19(3), 479-500.
157. Sureau, F.; Miskovsky, P.; Chinsky, L.; Turpin, P.Y. Hypericin-Induced Cell Photosensitization Involves an Intracellular pH Decrease. J. Am. Chem. Soc., 1996, 118(40), 9484-9487.
158. Newell, K.J.; Tannock, I.F. Reduction of intracellular pH as a possible mechanism for killing cells in acidic regions of solid tumors: effects of carbonylcyanide-3-chlorophenylhydrazone. Cancer Res., 1989, 49(16), 4477-44782.
159. Agostinis, P.; Assefa, Z.; Vantieghem, A.; Vandenheede, J.R.; Merlevede, W.; De Witte, P. Apoptotic and anti-apoptotic signaling pathways induced by photodynamic therapy with hypericin. Adv. Enzyme Regul., 2000, 40, 157-182.
160. Ali, S.M.; Olivo, M. Mechanisms of action of phenanthroperylene-quinones in photodynamic therapy (review). Int. J. Oncol., 2003, 22(6), 1181-1191.
161. Castano, A.P.; Demidova, T.N.; Hamblin, M.R. Mechanisms in photodynamic therapy: Part three - Photosensitizer pharmacokinetics, biodistribution, tumor localization and modes of tumor destruction. Photodiagn. Photodyn. Ther., 2005, 2(2), 91-106.
162. Krammer, B. Vascular effects of photodynamic therapy. Anticancer Res., 2001, 21(6B), 4271-4277.
163. van Duijnhoven, F.H.; Aalbers, R.I.; Rovers, J.P.; Terpstra, O.T.; Kuppen, P.J. The immunological consequences of photodynamic treatment of cancer, a literature review. Immunobiology, 2003, 207(2), 105-113.
164. Alecu, M.; Ursaciuc, C.; Halalau, F.; Coman, G.; Merlevede, W.; Waelkens, E.; de Witte, P. Photodynamic treatment of basal cell carcinoma and squamous cell carcinoma with hypericin. Anticancer Res., 1998, 18(6B), 4651-4654.
165. Liu, C.D.; Kwan, D.; Saxton, R.E.; McFadden, D.W. Hypericin and photodynamic therapy decreases human pancreatic cancer in vitro and in vivo. J. Surg. Res., 2000, 93(1), 137-143.
166. Calzavara-Pinton, P.G.; Venturini, M.; Sala, R. A comprehensive overview of photodynamic therapy in the treatment of superficial fungal
167. Jori, G.; Brown, S.B. Photosensitized inactivation of microorganisms. Photochem. Photobiol. Sci., 2004, 3(5), 403-405.
168. Sharman, W.M.; Allen, C.M.; van Lier, J.E. Photodynamic therapeutics: basic principles and clinical applications. Drug Discov. Today, 1999, 4(11), 507-517.
169. Wainwright, M. Photoinactivation of viruses. Photochem. Photobiol. Sci., 2004, 3(5), 406-411.